112 related articles for article (PubMed ID: 21378200)
1. Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors.
Langenberg MHG; Witteveen PO; Roodhart J; Lolkema MP; Verheul HMW; Mergui-Roelvink M; Brendel E; Krätzschmar J; Loembé B; Nol-Boekel A; Christensen O; Schellens JHM; Voest EE
Ann Oncol; 2011 Nov; 22(11):2508-2515. PubMed ID: 21378200
[TBL] [Abstract][Full Text] [Related]
2. Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.
Langenberg MH; Witteveen PO; Roodhart JM; Verheul HM; Mergui-Roelvink M; van der Sar J; Brendel E; Laferriere N; Schellens JH; Voest EE
Clin Cancer Res; 2010 Apr; 16(7):2187-97. PubMed ID: 20233884
[TBL] [Abstract][Full Text] [Related]
3. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors.
Steeghs N; Gelderblom H; Wessels J; Eskens FA; de Bont N; Nortier JW; Guchelaar HJ
Invest New Drugs; 2011 Feb; 29(1):137-43. PubMed ID: 19924384
[TBL] [Abstract][Full Text] [Related]
5. A phase I trial of vatalanib (PTK/ZK) in combination with bevacizumab in patients with refractory and/or advanced malignancies.
Jones SF; Spigel DR; Yardley DA; Thompson DF; Burris HA
Clin Adv Hematol Oncol; 2011 Nov; 9(11):845-52. PubMed ID: 22252616
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics.
Nwankwo N; Zhang Z; Wang T; Collins C; Resta L; Ermisch S; Day J; Decker R; Kornberg L; Nicol S; Thornton D; Armstrong DK; Carducci MA
Invest New Drugs; 2013 Jun; 31(3):653-60. PubMed ID: 22766773
[TBL] [Abstract][Full Text] [Related]
7. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.
Falchook GS; Wheler JJ; Naing A; Piha-Paul SA; Fu S; Tsimberidou AM; Hong DS; Janku F; Zinner R; Jiang Y; Huang M; Lin Q; Parkhurst K; Kurzrock R
Invest New Drugs; 2015 Feb; 33(1):215-24. PubMed ID: 25363205
[TBL] [Abstract][Full Text] [Related]
8. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
Azad NS; Posadas EM; Kwitkowski VE; Steinberg SM; Jain L; Annunziata CM; Minasian L; Sarosy G; Kotz HL; Premkumar A; Cao L; McNally D; Chow C; Chen HX; Wright JJ; Figg WD; Kohn EC
J Clin Oncol; 2008 Aug; 26(22):3709-14. PubMed ID: 18669456
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.
Hong DS; Garrido-Laguna I; Ekmekcioglu S; Falchook GS; Naing A; Wheler JJ; Fu S; Moulder SL; Piha-Paul S; Tsimberidou AM; Wen Y; Culotta KS; Anderes K; Davis DW; Liu W; George GC; Camacho LH; Percy Ivy S; Kurzrock R
Cancer; 2014 Jul; 120(14):2164-73. PubMed ID: 24752867
[TBL] [Abstract][Full Text] [Related]
10. Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors.
Paluri R; Madan A; Li P; Jones B; Saleh M; Jerome M; Miley D; Keef J; Robert F
Cancer Chemother Pharmacol; 2019 Mar; 83(3):551-559. PubMed ID: 30603797
[TBL] [Abstract][Full Text] [Related]
11. A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors.
Leong S; Moss RA; Bowles DW; Ware JA; Zhou J; Spoerke JM; Lackner MR; Shankar G; Schutzman JL; van der Noll R; Voest EE; Schellens JHM
Oncologist; 2017 Dec; 22(12):1491-1499. PubMed ID: 28798270
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors.
Wang F; Molina J; Satele D; Yin J; Lim VS; Adjei AA
Invest New Drugs; 2019 Aug; 37(4):658-665. PubMed ID: 30382439
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.
Vlahovic G; Meadows KL; Uronis HE; Morse MA; Blobe GC; Riedel RF; Zafar SY; Alvarez-Secord A; Gockerman J; Starodub AN; Ready NE; Anderson EL; Bendell JC; Hurwitz HI
Cancer Chemother Pharmacol; 2012 Jul; 70(1):95-102. PubMed ID: 22638798
[TBL] [Abstract][Full Text] [Related]
14. A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours.
Hong DS; Kurzrock R; Mulay M; Rasmussen E; Wu BM; Bass MB; Zhong ZD; Friberg G; Rosen LS
Oncotarget; 2014 Nov; 5(22):11154-67. PubMed ID: 25525888
[TBL] [Abstract][Full Text] [Related]
15. Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours.
Strumberg D; Schultheis B; Adamietz IA; Christensen O; Buechert M; Kraetzschmar J; Rajagopalan P; Ludwig M; Frost A; Steinbild S; Scheulen ME; Mross K
Br J Cancer; 2008 Nov; 99(10):1579-85. PubMed ID: 19002179
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
Roboz GJ; Giles FJ; List AF; Cortes JE; Carlin R; Kowalski M; Bilic S; Masson E; Rosamilia M; Schuster MW; Laurent D; Feldman EJ
Leukemia; 2006 Jun; 20(6):952-7. PubMed ID: 16617323
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors.
Zhu M; Molina JR; Dy GK; Croghan GA; Qi Y; Glockner J; Hanson LJ; Roos MM; Tan AD; Adjei AA
Invest New Drugs; 2020 Dec; 38(6):1755-1762. PubMed ID: 32328844
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.
Herbst RS; Johnson DH; Mininberg E; Carbone DP; Henderson T; Kim ES; Blumenschein G; Lee JJ; Liu DD; Truong MT; Hong WK; Tran H; Tsao A; Xie D; Ramies DA; Mass R; Seshagiri S; Eberhard DA; Kelley SK; Sandler A
J Clin Oncol; 2005 Apr; 23(11):2544-55. PubMed ID: 15753462
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial.
Keefe SM; Hoffman-Censits J; Cohen RB; Mamtani R; Heitjan D; Eliasof S; Nixon A; Turnbull B; Garmey EG; Gunnarsson O; Waliki M; Ciconte J; Jayaraman L; Senderowicz A; Tellez AB; Hennessy M; Piscitelli A; Vaughn D; Smith A; Haas NB
Ann Oncol; 2016 Aug; 27(8):1579-85. PubMed ID: 27457310
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors.
Strickler JH; Starodub AN; Jia J; Meadows KL; Nixon AB; Dellinger A; Morse MA; Uronis HE; Marcom PK; Zafar SY; Haley ST; Hurwitz HI
Cancer Chemother Pharmacol; 2012 Aug; 70(2):251-8. PubMed ID: 22744359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
